Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Related Citations for PubMed (Select 23210253)

1.

Acute coronary syndrome and rivaroxaban: not so fast...

[No authors listed]

Prescrire Int. 2012 Nov;21(132):260. No abstract available.

PMID:
23210253
2.

Rivaroxaban in patients with a recent acute coronary syndrome.

Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen M, Cook-Bruns N, Fox KA, Goto S, Murphy SA, Plotnikov AN, Schneider D, Sun X, Verheugt FW, Gibson CM; ATLAS ACS 2–TIMI 51 Investigators.

N Engl J Med. 2012 Jan 5;366(1):9-19. doi: 10.1056/NEJMoa1112277. Epub 2011 Nov 13.

3.

Rivaroxaban, an oral direct factor Xa inhibitor.

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.

Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . Review.

PMID:
18491993
4.

Rivaroxaban in the contemporary treatment of acute coronary syndromes.

Alexander D, Jeremias A.

Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. Review.

PMID:
21554163
5.

Rivaroxaban (Xarelto) for acute coronary syndrome.

[No authors listed]

Med Lett Drugs Ther. 2011 Dec 12;53(1379-1380):97.

PMID:
22173426
7.

Rivaroxaban for thromboprophylaxis.

Lotke PA.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009675
8.

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM; ATLAS ACS-TIMI 46 study group.

Lancet. 2009 Jul 4;374(9683):29-38. doi: 10.1016/S0140-6736(09)60738-8. Epub 2009 Jun 17.

PMID:
19539361
9.

Rivaroxaban in acute coronary syndromes--is it prime time?

Asrar ul Haq M, van Gaal WJ.

Expert Rev Cardiovasc Ther. 2014 Jun;12(6):649-58. doi: 10.1586/14779072.2014.910118. Epub 2014 Apr 19. Review.

PMID:
24746010
10.

Factor Xa inhibitors in acute coronary syndromes and venous thromboembolism.

Yong CM, Boyle AJ.

Curr Vasc Pharmacol. 2010 Jan;8(1):5-11. Review.

PMID:
19485937
11.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.

13.

Rivaroxaban versus enoxaparin after total knee arthroplasty.

Longo UG, Maffulli N, Denaro V.

Lancet. 2009 Aug 29;374(9691):681-2; author reply 683. doi: 10.1016/S0140-6736(09)61551-8. No abstract available.

PMID:
19716953
14.

Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study).

Romualdi E, Donadini MP, Ageno W.

Expert Rev Cardiovasc Ther. 2011 Jul;9(7):841-4. doi: 10.1586/erc.11.62.

PMID:
21809964
15.

Rivaroxaban for thromboprophylaxis.

ten Cate H, Hamulyak K.

N Engl J Med. 2008 Nov 13;359(20):2174-5; author reply 2176. No abstract available.

PMID:
19009676
17.

A new era in secondary prevention after acute coronary syndrome.

Roe MT, Ohman EM.

N Engl J Med. 2012 Jan 5;366(1):85-7. doi: 10.1056/NEJMe1112770. Epub 2011 Nov 13. No abstract available.

PMID:
22077849
18.

Rivaroxaban (Xarelto)--a new oral anticoagulant.

[No authors listed]

Med Lett Drugs Ther. 2011 Aug 22;53(1371):65-7. Review. No abstract available.

PMID:
21860366
19.

[The ATLAS ACS 2-TIMI 51 study].

Casella G, Pavesi PC, Magnani G, Ardissino D.

G Ital Cardiol (Rome). 2012 Oct;13(10):625-30. doi: 10.1714/1145.12614. Italian. No abstract available.

PMID:
23022965
20.

Rivaroxaban, the first oral, direct factor Xa inhibitor.

Fassiadis N.

Expert Opin Pharmacother. 2009 Dec;10(18):2945-6. doi: 10.1517/14656560903413559.

PMID:
19925048
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk